326 related articles for article (PubMed ID: 27369381)
1. Selectivity for strand-transfer over 3'-processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzyme-DNA interactions in the active site.
Métifiot M; Johnson BC; Kiselev E; Marler L; Zhao XZ; Burke TR; Marchand C; Hughes SH; Pommier Y
Nucleic Acids Res; 2016 Aug; 44(14):6896-906. PubMed ID: 27369381
[TBL] [Abstract][Full Text] [Related]
2. Exploring the molecular mechanism of cross-resistance to HIV-1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis.
Xue W; Jin X; Ning L; Wang M; Liu H; Yao X
J Chem Inf Model; 2013 Jan; 53(1):210-22. PubMed ID: 23231029
[TBL] [Abstract][Full Text] [Related]
3. Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout.
Osman N; Mesplède T; Oliveira M; Hassounah S; Wainberg MA; Brenner BG
AIDS; 2018 Aug; 32(13):1773-1780. PubMed ID: 29894388
[TBL] [Abstract][Full Text] [Related]
4. Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study.
Cheung PK; Shahid A; Dong W; Lepik KJ; Montaner JSG; Brockman MA; Brumme ZL; Brumme CJ
J Antimicrob Chemother; 2022 Mar; 77(4):979-988. PubMed ID: 35061879
[TBL] [Abstract][Full Text] [Related]
5. HIV drug resistance against strand transfer integrase inhibitors.
Anstett K; Brenner B; Mesplede T; Wainberg MA
Retrovirology; 2017 Jun; 14(1):36. PubMed ID: 28583191
[TBL] [Abstract][Full Text] [Related]
6. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572).
Hare S; Smith SJ; Métifiot M; Jaxa-Chamiec A; Pommier Y; Hughes SH; Cherepanov P
Mol Pharmacol; 2011 Oct; 80(4):565-72. PubMed ID: 21719464
[TBL] [Abstract][Full Text] [Related]
7. Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants.
Smith SJ; Zhao XZ; Burke TR; Hughes SH
Retrovirology; 2018 May; 15(1):37. PubMed ID: 29769116
[TBL] [Abstract][Full Text] [Related]
8. The R262K substitution combined with H51Y in HIV-1 subtype B integrase confers low-level resistance against dolutegravir.
Cutillas V; Mesplede T; Anstett K; Hassounah S; Wainberg MA
Antimicrob Agents Chemother; 2015 Jan; 59(1):310-6. PubMed ID: 25348535
[TBL] [Abstract][Full Text] [Related]
9. Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir.
Métifiot M; Maddali K; Naumova A; Zhang X; Marchand C; Pommier Y
Biochemistry; 2010 May; 49(17):3715-22. PubMed ID: 20334344
[TBL] [Abstract][Full Text] [Related]
10. Impact of resistance mutations on inhibitor binding to HIV-1 integrase.
Chen Q; Buolamwini JK; Smith JC; Li A; Xu Q; Cheng X; Wei D
J Chem Inf Model; 2013 Dec; 53(12):3297-307. PubMed ID: 24205814
[TBL] [Abstract][Full Text] [Related]
11. 2-Hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs), novel inhibitors of HIV integrase with a high barrier to resistance.
Desimmie BA; Demeulemeester J; Suchaud V; Taltynov O; Billamboz M; Lion C; Bailly F; Strelkov SV; Debyser Z; Cotelle P; Christ F
ACS Chem Biol; 2013; 8(6):1187-94. PubMed ID: 23517458
[TBL] [Abstract][Full Text] [Related]
12. Molecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity.
Johnson BC; Métifiot M; Pommier Y; Hughes SH
Antimicrob Agents Chemother; 2012 Jan; 56(1):411-9. PubMed ID: 22037850
[TBL] [Abstract][Full Text] [Related]
13. Close-up: HIV/SIV intasome structures shed new light on integrase inhibitor binding and viral escape mechanisms.
Engelman AN; Cherepanov P
FEBS J; 2021 Jan; 288(2):427-433. PubMed ID: 32506843
[TBL] [Abstract][Full Text] [Related]
14. Structure-Guided Optimization of HIV Integrase Strand Transfer Inhibitors.
Zhao XZ; Smith SJ; Maskell DP; Métifiot M; Pye VE; Fesen K; Marchand C; Pommier Y; Cherepanov P; Hughes SH; Burke TR
J Med Chem; 2017 Sep; 60(17):7315-7332. PubMed ID: 28737946
[TBL] [Abstract][Full Text] [Related]
15. The inhibition process of HIV-1 integrase by diketoacids molecules: Understanding the factors governing the better efficiency of dolutegravir.
El Khoury L; Piquemal JP; Fermandjian S; Maroun RG; Gresh N; Hobaika Z
Biochem Biophys Res Commun; 2017 Jul; 488(3):433-438. PubMed ID: 28478035
[TBL] [Abstract][Full Text] [Related]
16. Heterocycle amide isosteres: An approach to overcoming resistance for HIV-1 integrase strand transfer inhibitors.
Peese KM; Naidu BN; Patel M; Li C; Langley DR; Terry B; Protack T; Gali V; Lin Z; Samanta HK; Zheng M; Jenkins S; Dicker IB; Krystal MR; Meanwell NA; Walker MA
Bioorg Med Chem Lett; 2020 Feb; 30(3):126784. PubMed ID: 31761656
[TBL] [Abstract][Full Text] [Related]
17. Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase.
Quashie PK; Mesplède T; Han YS; Veres T; Osman N; Hassounah S; Sloan RD; Xu HT; Wainberg MA
Antimicrob Agents Chemother; 2013 Dec; 57(12):6223-35. PubMed ID: 24080645
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of HIV-1 integrase resistance to dolutegravir and potent inhibition of drug-resistant variants.
Li M; Oliveira Passos D; Shan Z; Smith SJ; Sun Q; Biswas A; Choudhuri I; Strutzenberg TS; Haldane A; Deng N; Li Z; Zhao XZ; Briganti L; Kvaratskhelia M; Burke TR; Levy RM; Hughes SH; Craigie R; Lyumkis D
Sci Adv; 2023 Jul; 9(29):eadg5953. PubMed ID: 37478179
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir.
Quashie PK; Mesplède T; Han YS; Oliveira M; Singhroy DN; Fujiwara T; Underwood MR; Wainberg MA
J Virol; 2012 Mar; 86(5):2696-705. PubMed ID: 22205735
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 Integrase Strand Transfer Inhibitors with Reduced Susceptibility to Drug Resistant Mutant Integrases.
Zhao XZ; Smith SJ; Maskell DP; Metifiot M; Pye VE; Fesen K; Marchand C; Pommier Y; Cherepanov P; Hughes SH; Burke TR
ACS Chem Biol; 2016 Apr; 11(4):1074-81. PubMed ID: 26808478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]